Identification of the Xenobiotic-Metabolizing Enzyme Arylamine N-Acetyltransferase 1 as a New Target of Cisplatin in Breast Cancer Cells: Molecular and Cellular Mechanisms of Inhibition

Arylamine N-acetyltransferase 1 (NAT1) is a phase II xenobiotic-metabolizing enzyme that plays an important role in the biotransformation of aromatic drugs and carcinogens. NAT1 activity has long been associated with susceptibility to various cancers. Evidence for a role of NAT1 in malignant progression has also been obtained, particularly for breast and prostate cancer. Cisplatin is widely used in chemotherapy against human cancers, and it is thought to act principally by forming DNA adducts. However, recent studies have suggested that some of the pharmacological and/or toxicological effects of cisplatin may be due to the direct targeting and inhibition of certain cellular enzymes. We show here that the exposure of breast cancer cells, known to express functional NAT1 enzyme, to therapeutically relevant concentrations of cisplatin impairs the catalytic activity of endogenous NAT1. Endogenous NAT1 was also found to be inactivated, in vivo, in the tissues of mice treated with cisplatin. Mechanistic studies with purified human NAT1 indicated that this inhibition resulted from the irreversible formation of a cisplatin adduct with the active-site cysteine residue of the enzyme. Kinetic studies suggested that NAT1 interacts rapidly with cisplatin, with a second-order rate inhibition constant of 700 M-1 min-1. This rate constant is one the highest ever reported for the reaction of cisplatin with a biological macromolecule. Few enzymes have been clearly shown to be inactivated by cisplatin. We provide here molecular and cellular evidence suggesting that NAT1 is one of the targets of cisplatin in cells.

[1]  Zhongmin Guo,et al.  Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer , 2007, Journal of bioenergetics and biomembranes.

[2]  J. Goodisman,et al.  Kinetic Study on the Reactions of Platinum Drugs with Glutathione , 2004, Journal of Pharmacology and Experimental Therapeutics.

[3]  M. Mimeault,et al.  Novel combination therapy against metastatic and androgen‐independent prostate cancer by using gefitinib, tamoxifen and etoposide , 2007, International journal of cancer.

[4]  J. States,et al.  Identification of N-Acetyltransferase 2 (NAT2) Transcription Start Sites and Quantitation of NAT2-Specific mRNA in Human Tissues , 2007, Drug Metabolism and Disposition.

[5]  M. Noble,et al.  Purification, characterization, and crystallization of an N-hydroxyarylamine O-acetyltransferase from Salmonella typhimurium. , 1998, Protein expression and purification.

[6]  J.-L. Jestin,et al.  Kinetic study of DNA binding of cisplatin and of a bicycloalkyl-substituted (ethylenediamine)dichloroplatinum(II) complex , 1998, JBIC Journal of Biological Inorganic Chemistry.

[7]  D. Grant,et al.  Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. , 1991, Molecular pharmacology.

[8]  J. Dairou,et al.  Reversible inhibition of the human xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 by S-nitrosothiols. , 2003, Biochemical and biophysical research communications.

[9]  J. Dairou,et al.  Redox Regulation of the Human Xenobiotic Metabolizing Enzyme Arylamine N-Acetyltransferase 1 (NAT1) , 2003, Journal of Biological Chemistry.

[10]  R. Gust,et al.  Preclinical and clinical studies on the use of platinum complexes for breast cancer treatment. , 2007, Anti-cancer agents in medicinal chemistry.

[11]  D. Hein,et al.  N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk , 2006, Oncogene.

[12]  J. Dairou,et al.  Peroxynitrite Irreversibly Inactivates the Human Xenobioticmetabolizing Enzyme Arylamine N-Acetyltransferase 1 (NAT1) in Human Breast Cancer Cells , 2004, Journal of Biological Chemistry.

[13]  J. Dupret,et al.  Structure and regulation of the drug-metabolizing enzymes arylamine N-acetyltransferases. , 2005, Current medicinal chemistry.

[14]  J. Dairou,et al.  Impairment of the activity of the xenobiotic‐metabolizing enzymes arylamine N‐acetyltransferases 1 and 2 (NAT1/NAT2) by peroxynitrite in mouse skeletal muscle cells , 2005, FEBS letters.

[15]  B. Turowski,et al.  Cisplatin tumor concentrations after intra‐arterial cisplatin infusion or embolization in patients with oral cancer , 2003, Clinical pharmacology and therapeutics.

[16]  C. Dwivedi,et al.  Effects of diallyl sulfide and diallyl disulfide on cisplatin‐induced changes in glutathione and glutathione‐S‐transferase activity , 1996, Anti-cancer drugs.

[17]  A. Harris,et al.  Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. , 2003, Molecular cancer research : MCR.

[18]  R. Minchin,et al.  Arylamine N-acetyltransferase I. , 2007, The international journal of biochemistry & cell biology.

[19]  J. Goodisman,et al.  Kinetic study on the reaction of cisplatin with metallothionein. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[20]  Arylamine N-acetyltransferases , 2007, Expert opinion on drug metabolism & toxicology.

[21]  Sadzuka Yasuyuki,et al.  Role of glutathione S-transferase isoenzymes in cisplatin-induced nephrotoxicity in the rat. , 1994 .

[22]  Moonil Kim,et al.  Cisplatin Inactivation of Caspases Inhibits Death Ligand-induced Cell Death in Vitro and Fulminant Liver Damage in Mice* , 2005, Journal of Biological Chemistry.

[23]  James Robinson,et al.  Arylamine N‐acetyltransferase 1 expression in breast cancer cell lines: A potential marker in estrogen receptor‐positive tumors , 2008, Genes, chromosomes & cancer.

[24]  D. Townsend,et al.  Glutathione S-transferase polymorphisms: cancer incidence and therapy , 2006, Oncogene.

[25]  D. Hein.  Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. , 2002, Mutation research.

[26]  Dar-Ren Chen,et al.  Effects of tamoxifen on DNA adduct formation and arylamines N-acetyltransferase activity in human breast cancer cells. , 2004, Research Communications in Molecular Pathology and Pharmacology.

[27]  J. Goodisman,et al.  Kinetic study of the reaction of cisplatin with thiols. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[28]  R. Cooper,et al.  Skeletal Muscles Express the Xenobiotic-metabolizing Enzyme Arylamine N-acetyltransferase , 2003, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[29]  R. Minchin,et al.  Induction of human arylamine N-acetyltransferase type I by androgens in human prostate cancer cells. , 2007, Cancer research.

[30]  Rosette Lidereau,et al.  Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma , 2004, Breast Cancer Research.

[31]  Y. Sadzuka,et al.  Role of glutathione S-transferase isoenzymes in cisplatin-induced nephrotoxicity in the rat. , 1994, Toxicology letters.

[32]  W. van der Vijgh,et al.  Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude mice. , 1998, European journal of cancer.

[33]  P. Bednarski,et al.  No Correlation between GSH Levels in Human Cancer Cell Lines and the Cell Growth Inhibitory Activities of Platinum Diamine Complexes , 2004, Archiv der Pharmazie.

[34]  W. Ens,et al.  Biochemical and Proteomics Approaches to Characterize Topoisomerase IIα Cysteines and DNA as Targets Responsible for Cisplatin-Induced Inhibition of Topoisomerase IIα , 2005, Molecular Pharmacology.

[35]  S. B. Prasad,et al.  Changes in glutathione-related enzymes in tumor-bearing mice after cisplatin treatment , 2004, Cell Biology and Toxicology.

[36]  F. Malecaze,et al.  The Xenobiotic-Metabolizing Enzymes Arylamine N-Acetyltransferases in Human Lens Epithelial Cells: Inactivation by Cellular Oxidants and UVB-Induced Oxidative Stress , 2005, Molecular Pharmacology.

[37]  D. Townsend,et al.  Efficacy of a glutathione S-transferase pi-activated prodrug in platinum-resistant ovarian cancer cells. , 2002, Molecular cancer therapeutics.

[38]  N. Katsilambros,et al.  Downregulation of interleukin-2 and apha-chain interleukin-2 receptor biosynthesis by cisplatin in human peripheral lymphocytes. , 1996, Clinical immunology and immunopathology.

[39]  R. Bose,et al.  Inhibition of Escherichia coli DNA polymerase‐I by the anti‐cancer drug cis‐diaminedichloroplatinum(II): what roles do polymerases play in cis‐platin‐induced cytotoxicity? , 1999, FEBS letters.

[40]  D. Bell,et al.  Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. , 1995, Cancer research.